Brokerages Set AVEO Pharmaceuticals, Inc. (AVEO) PT at $3.42
Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have earned an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $3.42.
A number of equities research analysts have recently weighed in on AVEO shares. Seaport Global Securities started coverage on shares of AVEO Pharmaceuticals in a research note on Friday. They issued a “buy” rating on the stock. FBR & Co restated a “buy” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research note on Friday, June 30th. Piper Jaffray Companies set a $2.00 target price on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Monday, July 24th. Finally, ValuEngine upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th.
A number of large investors have recently bought and sold shares of AVEO. Sabby Management LLC acquired a new stake in AVEO Pharmaceuticals during the 1st quarter worth approximately $513,000. Perceptive Advisors LLC boosted its position in AVEO Pharmaceuticals by 64.3% during the 1st quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 2,000,000 shares during the period. Paloma Partners Management Co acquired a new stake in AVEO Pharmaceuticals during the 1st quarter worth approximately $184,000. UBS Oconnor LLC acquired a new stake in AVEO Pharmaceuticals during the 1st quarter worth approximately $291,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in AVEO Pharmaceuticals during the 2nd quarter worth approximately $289,000. Institutional investors and hedge funds own 53.76% of the company’s stock.
AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.4193% during midday trading on Friday, hitting $3.7855. 1,450,746 shares of the company were exchanged. The firm’s 50-day moving average price is $3.61 and its 200-day moving average price is $1.93. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $4.24. The stock’s market capitalization is $447.85 million.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.